Biotech Recovery Boosted by Deals

The article focuses on the resurgence of Boston’s biotech industry, driven by a wave of high-value mergers and acquisitions. After a slowdown during the pandemic, deal activity has surged, with over $85 billion in large deals announced globally in the first half of 2026, surpassing last year's totals. This renewed M&A momentum is attracting major pharma companies, addressing patent expiries, and increasing local industry activity, which is expected to generate jobs and reduce lab vacancies over time.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل